NARS-3′
NARS-3′ is an orally active reversible xanthine oxidase (XO) inhibitor with the IC50 of 21.01 μM. NARS-3′ can competitively inhibit XO activity and reduce uric acid production. NARS-3′ can reduce renal damage in hyperuricemia mice. NARS-3′ can be used for the study of hyperuricemia.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2702589-46-4
- Formule: C15H11NaO8S
- Masse moléculaire:374.30
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
NARS-3′ (0-100 μM) exhibits dose-dependent inhibition on XO activity[1].
NARS-3′ (0-40 μM) can bind to the active site of XO and compete with xanthine substrates during the catalytic process[1].
NARS-3′ could cause the conformational changes in XO[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Potassium oxonate (250 mg/kg) injected the male Kunming mice (4 weeks)[1].
-
Dosage:0.3 % carboxymethyl cellulose sodium solution
-
Administration:Oral gavage (i.g.); once daily for a week
-
Result:Reduced serum UA levels to 56.26 μM and reduced XO activity to 9.21 U/L.
Lowered serum CRE levels to 7.85 μM and reduce pathological damage to the kidneys.
Chemical Information
-
CAS No. 2702589-46-4
-
Masse moléculaire 374.30
-
Formule C15H11NaO8S
-
SMILES
O=C1CC(OC2=CC(O)=CC(O)=C12)C3=CC(S(=O)(O[Na])=O)=C(C=C3)O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)